Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $140

Benzinga · 2d ago
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $95 to $140.